$85.81
Value $109B
CVS and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$85.81
Value $109B
$278.70
Value $672B
CVS Health (CVS) has a market value of $109B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, CVS moved +13.6% and JNJ +45.4%. The P/E is 9.9 for CVS and 41.7 for JNJ. Dividend yield: CVS 3.10%, JNJ 1.89%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CVS$109B
JNJ$672B
JNJ is 6.2 times CVS
Revenue, 12 months
CVS$421B
JNJ$99.3B
CVS is 4.2 times JNJ
Net income, 12 months
CVS$11.0B
JNJ$16.1B
JNJ is 1.5 times CVS
Operating margin
CVS3.6%
JNJ–
ROIC
CVS9.8%
JNJ12.4%
2.6 points apart
P/E
CVS9.9
JNJ41.7
JNJ is 4.2 times CVS
Dividend yield
CVS3.1%
JNJ1.9%
1.2 points apart
5-year return
CVS+9.1%
JNJ+97.0%
87.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CVS+9.1%
JNJ+97.0%
| Period | CVSWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +13.6%Price +10.3% | +45.4%Price +42.2% |
| 3 years since November 17, 2023 | +39.5%+11.7% a yearPrice +24.7% | +102.6%+26.5% a yearPrice +86.1% |
| 5 years since November 16, 2021 | +9.1%+1.8% a yearPrice -7.6% | +97.0%+14.5% a yearPrice +71.3% |
| 10 years since November 17, 2016 | +57.6%+4.7% a yearPrice +15.5% | +213.7%+12.1% a yearPrice +139.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CVSCVS HealthJNJJohnson & Johnson
| Price | $85.81 | $278.70 |
|---|---|---|
| Market value | $109B | $672B |
| Enterprise value (EV) | $155B | $699B |
| P/E | 9.9 | 41.7 |
| P/E, 5-year median | 17.1 | 21.9 |
| P/B | 1.4 | 8.2 |
| EV/EBIT | 10.3 | 39.4 |
| Free cash flow yield | 14.3% | 3.1% |
| Revenue, 12 months | $421B | $99.3B |
|---|---|---|
| Net income, 12 months | $11.0B | $16.1B |
| Free cash flow, 12 months | $15.6B | $20.6B |
| Earnings per share, 12 months | $8.61 | $6.59 |
| Revenue growth, year on year | 7.9% | 6.1% |
| Revenue growth a year, past | +8.4%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | -23.9%over 5 years | +14.9%over 5 years |
| Gross margin | 44.2% | 67.6% |
|---|---|---|
| Operating margin | 3.6% | – |
| Net margin | 2.6% | 16.2% |
| ROIC | 9.8% | 12.4% |
| ROE | 14.3% | 19.7% |
| Cash | $14.9B | $17.2B |
|---|---|---|
| Total debt | $75.3B | $44.7B |
| Net debt / EBITDA | 2.3 | 1.1 |
| Interest cover | 4.9× | 18.0× |
| Dividend yield | 3.1% | 1.9% |
|---|---|---|
| Dividend per share, 12 months | $2.66 | $5.28 |
| Dividend growth a year, past | +5.9%over 5 years | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | 3.1% | 2.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($672B) is about 6.2 times CVS Health ($109B), at today's prices.
Since November 17, 2016, CVS's price moved +15.5% and JNJ's +139.1%. With dividends: CVS +57.6% (+4.7% a year), JNJ +213.7% (+12.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 3.10% for CVS Health and 1.89% for Johnson & Johnson. Over the last twelve months they paid $2.66 and $5.28 per share.
At today's price, the P/E is 9.9 for CVS and 41.7 for JNJ. The median of the last five years was 17.1 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 2.6% for CVS Health and 16.2% for Johnson & Johnson, and the operating margin 3.6% and –. Revenue was $421B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.